Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.

Vashishtha, A.; Patel, Premal H.; Yu, Wei; Bothos, John; Simpson, Joe Leigh; Maneatis, Thomas; Doessegger, Lucette; Peterson, Amy; Clément-Duchêne, Christelle; Robinet, G.; Krzakowski, Maciej; Blumenschein, G. R.; Goldschmidt, Jerome H.; Daniel, D. B.; Spigel, David R.

doi:10.1200/jco.2011.29.15_suppl.7604

Search citation statements

Order By: Relevance

Paper Sections

Select...

New Agents For Overcoming Ar1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2017

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MET activates ERBB3 and the PI3K/AKT pathway independent of EGFR [ 16 ]. MetMAb [ 17 ] and ARQ197 (tivantinib) [ 18 ] are the most prominent MET inhibitors, but they have not been investigated for overcoming TKI resistance.…”

Section: New Agents For Overcoming Armentioning

confidence: 99%

Novel agents and strategies for overcoming EGFR TKIs resistance

Niu

2014

Exp Hematol Oncol

View full text Add to dashboard Cite

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients with EGFR mutations treated with EGFR TKIs is significantly prolonged compared with that of patients who underwent standard chemotherapy. However, all patients who initially respond to EGFR TKIs eventually develop acquired resistance (AR). Many small molecule agents and monoclonal antibodies (McAb) targeting signaling pathways are potential therapeutic regimens for overcoming resistance, and various therapeutic strategies are used in clinical practice. Here we review the novel agents and therapeutic strategies for overcoming AR to EGFR TKIs.

show abstract

Section: New Agents For Overcoming Armentioning

confidence: 99%